Title: USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS

Abstract

The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders, methods of medical treatment using such an NK-1 receptor antagonist and pharmaceutical compositions comprising it.
| AL | Albania                      | ES | Spain                     |
| AM | Armenia                     | FI | Finland                   |
| AT | Austria                     | FR | France                    |
| AU | Australia                   | GA | Gabon                     |
| AZ | Azerbaijan                  | GB | United Kingdom            |
| BA | Bosnia and Herzegovina      | GE | Georgia                   |
| BB | Barbados                    | GH | Ghana                     |
| BE | Belgium                     | GN | Guinea                    |
| BF | Burkina Faso                | GR | Greece                    |
| BG | Bulgaria                    | HU | Hungary                   |
| BJ | Benin                       | IE | Ireland                   |
| BR | Brazil                      | IL | Israel                    |
| BY | Belarus                     | IS | Iceland                   |
| CA | Canada                      | IT | Italy                     |
| CF | Central African Republic    | JP | Japan                     |
| CG | Congo                       | KE | Kenya                     |
| CH | Switzerland                 | KG | Kyrgyzstan                |
| CI | Côte d'Ivoire               | KP | Democratic People's       |
| CM | Cameroon                    | KR | Republic of Korea         |
| CN | China                       | KZ | Kazakhstan                |
| CU | Cuba                        | LC | Saint Lucia               |
| CZ | Czech Republic              | LI | Liechtenstein             |
| DE | Germany                     | LK | Sri Lanka                 |
| DK | Denmark                     | LR | Liberia                   |
| EE | Estonia                     | LS | Lesotho                   |
| LT | Lithuania                   | LU | Luxembourg                |
| LV | Latvia                      | MC | Monaco                    |
| MD | Republic of Moldova         | MG | Madagascar                |
| MK | The former Yugoslav Republic of Macedonia |
| ML | Mali                        | MN | Mongolia                  |
| MR | Mauritania                  | MW | Malawi                    |
| MX | Mexico                      | NE | Niger                     |
| NL | Netherlands                 | NO | Norway                    |
| NZ | New Zealand                 | PL | Poland                    |
| PT | Portugal                    | RO | Romania                   |
| RU | Russian Federation          | SD | Sudan                     |
| SE | Sweden                      | SG | Singapore                 |
| SI | Slovenia                    | SK | Slovakia                  |
| SN | Senegal                     | SZ | Swaziland                 |
| TD | Chad                        | TG | Togo                      |
| TJ | Tajikistan                  | TM | Turkmenistan               |
| TR | Turkey                      | TT | Trinidad and Tobago       |
| UA | Ukraine                     | UG | Uganda                    |
| US | United States of America    | VN | Viet Nam                  |
| UZ | Uzbekistan                  | YU | Yugoslavia                |
| ZW | Zimbabwe                    |
USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS

This invention relates to the treatment or prevention of certain cognitive disorders by the administration of a specific class of NK-1 receptor antagonists.

Cognitive disorders include dementia, amnestic disorders and cognitive disorders not otherwise specified. The prominent disturbance associated with these conditions is a clinically significant deficit in cognition or memory that represents a significant change from a previous level of functioning.

For instance, dementia is now defined as a syndrome consisting of progressive impairment in two or more areas of cognition (i.e. memory, language, visuospatial and perceptual ability, thinking and problem solving, and personality) sufficient to interfere with work, social function or relationships.

An amnestic disorder is characterised by memory impairment in the absence of other significant cognitive impairments.

Pharmacological treatment of such cognitive disorders is poorly developed. In some instances, antidepressants, hypnotics or antipsychotics may be used in order to manage specific behavioural disturbances associated with the cognitive disorder. Such treatments, however, may be compromised by the side effects associated with these classes of pharmacological agent and, as such, are far from ideal means for treating cognitive disorders.

Neurokinin 1 (NK-1; substance P) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins, and in particular substance P. Examples of conditions in which substance P has been implicated include disorders of the central nervous system such as anxiety,
depression and psychosis (see, for instance, International (PCT) patent specification Nos. WO 95/16679, WO 95/18124 and WO 95/23798).

More recently, International (PCT) patent specification No. WO 96/24353 (published 15th August 1996) suggests that a more efficacious and safe treatment of psychiatric disorders would be achieved using a combination of a tachykinin antagonist and a serotonin agonist or selective serotonin reuptake inhibitor (SSRI). However, such as regimen would not be free of side-effects due to the serotonin agonist or SSRI.

NK-1 receptor antagonists are described in published European Patent Specification Nos. 0 360 390, 0 394 989, 0 429 366, 0 443 132, 0 482 539, 0 512 901, 0 512 902, 0 514 273, 0 514 275, 0 517 589, 0 520 555, 0 522 808, 0 528 495, 0 532 456, 0 533 280, 0 536 817, 0 545 478, 0 577 394, 0 590 152, 0 599 538, 0 610 793, 0 634 402, 0 686 629, 0 693 489, 0 694 535, 0 699 655, 0 699 674, 0 707 006, 0 708 101, 0 714 891, 0 723 959, 0 733 632 and 0 776 893; and in International Patent Specification Nos. 90/05525, 90/05729, 91/09844, 91/18899, 92/01688, 92/06079, 92/12151, 92/15585, 92/17449, 92/20661, 92/20676, 92/21677, 93/00330, 93/00331, 93/01159, 93/01165, 93/01169, 93/01170, 93/06099, 93/09116, 93/10073, 93/14113, 93/18023, 93/19064, 93/21155, 93/21181, 93/23380, 93/24465, 94/01402, 94/02461, 94/03429, 94/03445, 94/04494, 94/04496, 94/05625, 94/07843, 94/10165, 94/10167, 94/10168, 94/10170, 94/11368, 94/13639, 94/13663, 94/14767, 94/15903, 94/19320, 94/19323, 94/20500, 94/26735, 94/26740, 94/29309, 95/02959, 95/04040, 95/04042, 95/06645, 95/07886, 95/07908, 95/08549, 95/11880, 95/14017, 95/15311, 95/16679, 95/17382, 95/18124, 95/18129, 95/19344, 95/20575, 95/21819, 96/22525, 95/23798, 95/26338, 95/28418, 95/30674, 95/30687, 96/05193, 96/05203, 96/06094, 96/07649, 96/10562, 96/16939, 96/18643, 96/20197, 96/21661, 96/29304, 96/29317, 96/29326, 96/29328, 96/31214, 96/32385, 96/37489, 97/01553, 97/01554, 97/03066, 97/08144, 97/14671, 97/17362, 97/18206, 97/19084, 97/19942 and 97/21702; and in
British Patent Specification Nos. 2 266 529, 2 268 931, 2 269 170, 2 269 590, 2 271 774, 2 292 144, 2 293 168, 2 293 169, and 2 302 689.

In view of the shortcomings of existing therapy, there is a need for new, safe and effective treatment for cognitive disorders.

The present invention provides the use of a CNS penetrant NK-1 receptor antagonist in an oral, once-a-day medicament for the treatment of cognitive disorders. The compounds of this class advantageously exhibit a rapid onset of action and a reduced side-effect profile when compared against conventional antidepressant or antipsychotic agents.

In particular, the present invention provides a means for the identification of NK-1 receptor antagonists which would be effective in an oral once-a-day medicament for the treatment of cognitive disorders. The aforementioned patent specifications which describe NK-1 receptor antagonists provide no reliable method for the identification of such compounds.

The exceptional pharmacology of the class of NK-1 receptor antagonists of use in the present invention enables the treatment of cognitive disorders, without the need for concomitant therapy using tricyclic antidepressants or monoamine oxidase inhibitors, or antipsychotic agents, or in particular, without the need for concomitant use of a serotonin agonist or an SSRI.

Furthermore, the exceptional pharmacology of the class of NK-1 receptor antagonists of use in the present invention results in a rapid onset of action.

The present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist (as hereinafter defined) for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders.

The present invention also provides a method for the treatment or prevention of cognitive disorders, which method comprises the oral administration to a patient in need of such treatment of an effective
amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist (as hereinafter defined).

In a further aspect of the present invention, there is provided an oral pharmaceutical composition for the treatment of cognitive disorders which comprises an orally active, long acting, CNS-penetrant NK-1 receptor antagonist (as hereinafter defined), together with a pharmaceutically acceptable carrier or excipient.

There exists a patient population in whom cognitive disorders are inadequately treated with existing antidepressant therapy. Furthermore, some patients may be adversely affected by the side-effects of existing antidepressant drugs.

The present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders in a patient who is non-responsive to heterocyclic antidepressants (TCAs, tetracyclics, and the like), SSRIs, serotonin agonists or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs, or for whom heterocyclic antidepressants (TCAs, tetracyclics, and the like), SSRIs, serotonin agonists or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs are contraindicated.

The present invention also provides a method for the treatment or prevention of cognitive disorders in a patient who is non-responsive to heterocyclic antidepressants (TCAs, tetracyclics, and the like), SSRIs, serotonin agonists or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs, or for whom heterocyclic antidepressants (TCAs, tetracyclics, and the like), SSRIs, serotonin agonists or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs are contraindicated, which method comprises oral
administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.

Furthermore, there exists a patient population in whom cognitive disorders are inadequately treated with existing antipsychotic therapy. Furthermore, some patients may be adversely affected by the side-effects of antipsychotic drugs.

The present invention accordingly provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders in a patient who is non-responsive to antipsychotic agents, or for whom antipsychotic agents are contraindicated.

The present invention also provides a method for the treatment or prevention of cognitive disorders in the patient who is non-responsive to antipsychotic agents, or for whom antipsychotic agents are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.

As used herein, the term “cognitive disorders” includes dementia, amnestic disorders and cognitive disorders not otherwise specified.

In particular, the term “cognitive disorders” includes dementia caused by degenerative disorders, lesions, trauma, infections, vascular disorders, toxins, anoxia, vitamin deficiency and endocrine disorders.

Specific examples of these causes include degenerative disorders such as Alzheimer's disease, multiple sclerosis, Parkinson's disease, normal pressure hydrocephalus and Huntington's chorea; space occupying lesions including tumors and chronic subdural haematoma; trauma including severe head injury; infections including postencephalitis and syphilis; vascular disorders including multi-infarct dementia; toxins including alcohol; anoxia caused by cardiac arrest and carbon monoxide poisoning.
vitamin deficiencies including lack of vitamin B\textsubscript{12}; and endocrine disorders including hypothyroidism.

Furthermore, the term "cognitive disorders" includes amnestic disorders caused by alcohol (Korsakoff psychosis) and other causes of thiamine deficiency; bilateral temporal lobe damage due to herpes simplex encephalitis and other limbic encephalitis, neuronal loss secondary to anoxia/hypoglycaemia/severe convulsions, and surgery; degenerative disorders including Alzheimer's and Pick's diseases; vascular disorders including bilateral infarction, hippocampal infarction and bilateral cingulate cortex infarction; and pathology around ventricle III including tumors, chronic meningitis and neurosarcoidosis.

Also, as used herein, the term "cognitive disorders" includes cognitive impairment resulting from other medical conditions, most especially resulting from depression and/or anxiety.

As used herein, the term "treatment" refers both to the treatment and to the prevention or prophylactic therapy of the aforementioned conditions.

Preferred NK-1 receptor antagonists for use in the present invention are selected from the classes of compounds described in European Patent Specification No. 0 577 394, and International Patent Specification Nos. 95/08549, 95/18124, 95/23798 and 96/05181, and International Patent Application No. PCT/GB97/01630. The preparation of such compounds is fully described in the aforementioned publications.

Particularly preferred NK-1 receptor antagonists of use in the present invention include:

2-(S)-(3,5-bis(trifluoromethyl)benzyl)oxy)-3(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;
2-(S)-(3,5-bis(trifluoromethyl)benzyl)oxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolomethyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(4-monophosphoryl-5-oxo-1H-1,2,4-triazolomethyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(1-monophosphoryl-5-oxo-1H-1,2,4-triazolomethyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(2-monophosphoryl-5-oxo-1H-1,2,4-triazolomethyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxphosphoryl-1H-1,2,4-triazolomethyl)morpholine;

2-(S)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(1-monophosphoryl-5-oxo-4H-1,2,4-triazolomethyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N,N-dimethylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;

(3S,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl-1-oxa-7-aza-spiro[4,5]decane;

(3R,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl-1-oxa-7-aza-spiro[4,5]decane;

or a pharmaceutically acceptable salt thereof.

Full descriptions of the preparation of the NK-1 receptor antagonists which may be employed in the present invention may be found in the references cited herein.

Suitable pharmaceutically acceptable salts of the NK-1 receptor antagonists of use in the present invention include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable non-toxic acid such as
hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. Salts of amine groups may also comprise the quaternary ammonium salts in which the amino nitrogen atom carries an alkyl, alkenyl, alkynyl or aralkyl group. Where the compound carries an acidic group, for example a carboxylic acid group, the present invention also contemplates salts thereof, preferably non-toxic pharmaceutically acceptable salts thereof, such as the sodium, potassium and calcium salts thereof.

Preferably the compositions containing an NK-1 receptor antagonist of use according to the present invention are in unit dosage forms such as tablets, pills, capsules, wafers and the like. Additionally, the NK-1 receptor antagonists of use according to the present invention may be presented as granules or powders for extemporaneous formulation as volume defined solutions or suspensions. Alternatively, the NK-1 receptor antagonists of use according to the present invention may be presented in ready-prepared volume defined solutions or suspensions. Preferred forms are tablets and capsules.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof.

When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the
novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, peanut oil or soybean oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

Compositions of the present invention may also be administered via the buccal cavity using conventional technology, for example, absorption wafers.

Compositions in the form of tablets, pills, capsules or wafers for oral administration are particularly preferred.

A minimum dosage level for the NK-1 receptor antagonist is about 1mg per day, preferably about 5mg per day and especially about 10mg per day. A maximum dosage level for the NK-1 receptor antagonist is about 1500mg per day, preferably about 1000mg per day and especially about 500mg per day. The compounds are administered once a day.

It will be appreciated that the amount of the NK-1 receptor antagonist required for use in the treatment or prevention of cognitive
disorders will vary not only with the particular compounds or compositions selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the patient’s physician or pharmacist.

Two compounds of use in the present invention which are described in International Patent Application No. PCT/GB97/01630 may be prepared according to the following methods:

10

preparation 1

(2S)-1-tert-Butoxycarbonyl-2-phenylpiperidin-3-one

Dimethyl sulfoxide (20.80ml, 22.90g, 29.3mmol) in dichloromethane (75ml) was added dropwise to a cooled (-70°C) solution of oxalyl chloride (13.95ml, 20.30g, 160mmol) in dichloromethane (350ml). The mixture was stirred at -70°C for 15 minutes, then (2S,3S)-1-tert-butoxycarbonyl-3-hydroxy-2-phenylpiperidine (prepared by the method described in European Patent Specification number 0 528 495-A; 36.91g, 133mmol) in dichloromethane (150ml) was added dropwise. The mixture was stirred at -70 °C for 20 minutes, then allowed to warm to -30°C. The mixture was cooled to -50 °C and triethylamine (55.95ml, 40.45g, 400mmol) was added slowly. The mixture was allowed to warm to 0°C and diluted with ice-cooled dichloromethane (250ml). The mixture was washed with ice cold aqueous citric acid solution (5%, 2x300ml) and water (300ml), dried (MgSO₄), and the solvent was evaporated under reduced pressure to give the title compound as a yellow oil (42.3g), which was used immediately without further purification. ¹H NMR (250MHz, CDCl₃) δ 7.5-7.3 (5H, m), 5.8 (1H, br s), 4.2 (1H, br s), 3.4 (1H, m), 2.6 (2H, m), 2.0 (2H, m), and 1.54 (9H, s).
PREPARATION 2

(2S,3R)-1-tert-Butoxycarbonyl-3-hydroxy-3-(2-methylene-3-phenoxypropyl)-2-phenylpiperidine

A solution of 3-(chloromagnesio)-2-(phenoxymethyl)-1-propene in THF (0.91M, 3ml) (Louw et al., Tetrahedron, 48, 6087-6104, 1992, prepared from 2.74mmol of 3-choloro-2-(phenoxymethyl)-1-propene was slowly added to a solution of (2S)-1-tert-butoxycarbonyl-2-phenylpiperidin-3-one (Preparation 1) in THF (3ml). The mixture was stirred at room temperature for 1 hours, then saturated aqueous ammonium chloride (20ml) was added and the mixture was extracted with ethyl acetate (20ml). The organic phase was washed with brine, dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with hexane/ethyl acetate (100:0 increasing to 80:20) to give the title compound. ¹H NMR (360MHz, CDCl₃) δ 7.48 (2H, d, J=6.9 Hz), 7.35-7.2 (6H, m), 6.9-6.88 (3H, m), 5.4 (1H, s), 5.15 (2H, d, J=13.7 Hz), 4.61 (2H, s), 4.11 (2H, m), 3.17 (1H, m), 2.66 and 2.59 (2H, AB d, J=14.0 Hz), 1.95 (2H, m), 1.79 (2H, m), and 1.36 (9H, s). m/z (ES⁺) 424 (M+1).

PREPARATION 3

(5R,6S)-3-Methylene-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4,5]decane

To a cooled (-80 °C) solution of (2S,3R)-1-tert-butoxycarbonyl-3-hydroxy-3-(2-methylene-3-phenoxypropyl)-2-phenylpiperidine (Preparation 2, 1.53g, 3.62mmol) in THF (20ml) was added n-butyl lithium (2.5M in hexanes, 1.45ml, 3.62mmol) followed by a solution of zinc chloride (0.5M in THF, 7.24ml, 3.62mmol). The solution was allowed to warm to room temperature and tetrakis(triphenylphosphine)palladium (0) (0.23g, 0.2mmol) was added. The mixture was degassed with bubbling nitrogen and heated under reflux for 16 hours. The mixture was cooled and the solvent was evaporated under reduced pressure. The residue was
partitioned between ethyl acetate and 2M sodium hydroxide. The organic phase was washed with saturated brine, dried (MgSO₄) and purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 5%).

Evaporation of the fractions gave \((6S,5R)-3\text{-methylene-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane}\). \(^1\text{H} \, \text{NMR} \, (360\text{MHz, CDCl}_3)\) δ 7.58 (2H, d, \(J=8.4\ \text{Hz}\)), 7.32-7.21 (3H, m), 5.23 (1H, s), 5.06 (1H, m), 4.97 (1H, m), 4.39 (2H, AB d, \(J=13.3\ \text{Hz}\)), 3.99 (1H, dd, \(J=13.3, 4.48\ \text{Hz}\)), 2.83 (1H, Ab d, \(J=15.5\ \text{Hz}\)), 2.7 (1H, td, \(J=12.5, 3.93\ \text{Hz}\)), 2.5 (1H, Ab d, \(J=15.4\ \text{Hz}\)), 2.15 (2H, td, \(J=12.\), .4 Hz), 1.69 (2H, m), and 1.46 (9H, s). m/z (ES\(^+\)) 329 (M+2H, \(^1\text{BuOCO}\).

**PREPARATION 4**

\((5R,6S)-3\text{-Keto-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane}\)

Through a cooled (-80 °C) solution of \((5R,6S)-3\text{-methylene-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane}\) (Preparation 3; 0.665g) in dichloromethane (5ml) and methanol (5ml) was bubbled a mixture of ozone and oxygen for 45 minutes. After the solution had been purged with nitrogen, dimethyl sulphide (0.5ml) was added and then stirred under nitrogen at room temperature for 16 hours. The solvent was removed \textit{in vacuo} and the residue partitioned between ethyl acetate and water. The organic phase was dried (MgSO₄), evaporated and the residue purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 10%).

Evaporation of the fractions gave the title compound. \(^1\text{H} \, \text{NMR} \, (250\text{MHz, CDCl}_3)\) δ 7.58 (2H, d, \(J=6.2\ \text{Hz}\)), 7.37-7.26 (3H, m), 5.3 (1H, s), 4.15 and 4.09 (2H, AB d, \(J=17.4\ \text{Hz}\)), 3.97 (1H, m), 2.80 (1H, td, \(J=12.9, 4.0\ \text{Hz}\)), 2.74 and 2.48 (2H, AB d, \(J=18.1\ \text{Hz}\)), 2.29 (2H, m), 1.88-1.63 (2H, m), and 1.44 (9H, s). m/z (ES\(^+\)) 332 (M+1).
PREPARATION 5

(5R,6S)-3-Trifluoromethylsulfonyloxy-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene

To a cooled (-80 °C) solution of 1M sodium hexamethyldisilazide (0.38ml, 0.38mmol) in THF was added a solution of (5R,6S)-3-keto-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 4; 0.105mg, 0.319mmol) in THF (3ml). The solution was stirred for 1 hour at -80°C then a solution of 2-[N,N-bis(trifluoromethylsulfonyl)amino]-5-chloropyridine (0.163g, 0.415mmol) in THF (3ml) was added. The solution was stirred at -80°C for 30 minutes then at room temperature for 30 minutes before being quenched by addition of saturated ammonium chloride solution and ethyl acetate. The dried (MgSO4) organic phase was purified by chromatography on a column containing silica gel (eluting with hexane containing increasing proportions of ethyl acetate between 0% to 5%). Evaporation of the fractions gave the title compound. 1H NMR (360MHz, CDCl3) δ 7.4 (2H, d, J=7.3 Hz), 7.3-7.22 (3H, m), 6.01 (1H, t, J=2.13 Hz), 5.13 (1H, s), 4.56 and 4.26 (2H, ABdd, J=12.4, 1.97 Hz), 4.10 (1H, dt, J=12.6, 4.22 Hz), 3.00 (1H, m), 2.28-2.04 (2H, m), 1.88-1.76 (2H, m), and 1.37 (9H, s). m/z (ES+) 464 (M+1).

PREPARATION 6

(5R,6S)-3-Trimethylstannyl-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene

To a degassed solution of (5R,6S)-3-trifluoromethylsulfonyloxy-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene (Preparation 5; 0.482g, 1.04mmol), lithium chloride (0.264g, 6.25mmol), lithium carbonate (0.076g) and hexamethyl distannane (0.96g, 2.9mmol) in THF (10ml) was added triphenylphosphine palladium (0) (0.06g). The solution was degassed and then heated at 60°C for 5 hours under nitrogen. Water (20ml) and ethyl acetate (20ml) were added and the dried organic phase was purified by chromatography on a column containing silica gel (eluting
with hexane containing increasing proportions of ethyl acetate between 0% to 5%). Evaporation of the fractions gave the title compound as a crystalline solid. $^1$H NMR (360MHz, CDCl$_3$) δ 7.25 (2H, d, $J$=7.3 Hz), 7.1-7.0 (3H, m), 5.83 (1H, t, $J$=2.5 Hz), 4.78 (1H, s), 4.48 and 4.02 (2H, dd, $J$=12.9, 2.3 Hz), 3.96 (1H, dd, $J$=6.16, 13.4 Hz), 2.95 (1H, td, $J$=13.3, 4.5 Hz), 1.84 (1H, m), 1.68 (1H, m), 1.60 (2H, m), 1.19 (9H, s), and 0.0 (6H, s).

**PREPARATION 7**

(2S,3R)-1-**tert**-Butoxycarbonyl-3-(3-hydroxypropyn-1-yl)-2-phenylpiperidin-3-ol

O-Trimethylsilylpropargyl alcohol (24.51ml, 20.47g, 160ml) was added slowly to a cooled (-10°C) solution of ethylmagnesium bromide (1M in tetrahydrofuran, 160ml, 160mmol). The mixture was stirred at 0°C for 20 minutes, then at room temperature for 2 hours. The mixture was cooled to -10°C and a solution of (2S)-1-**tert**-butoxycarbonyl-2-phenylpiperidin-3-one (Preparation 1; 42.3g) in tetrahydrofuran (200ml) was added dropwise over 30 minutes. (Internal temperature below -5°C). The mixture was stirred at room temperature for 14 hours, poured into water (300ml) and saturated aqueous ammonium chloride (300ml) and extracted with ethyl acetate (2x300ml). The combined organic fractions were washed with brine (300ml), dried (MgSO$_4$) and the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (500ml) and a solution of tetrabutylammonium fluoride (1M in THF, 160ml, 160mmol) was added dropwise. The mixture was stirred at room temperature for 30 minutes, water (300ml) was added, and the layers were separated. The aqueous layer was extracted with ethyl acetate (2x300ml) and the combined organic fractions were washed with water (300ml) and brine (300ml), dried (MgSO$_4$) and the solvent was evaporated under reduced pressure to give the crude title compound as an orange oil (45g). The crude material was purified by flash column chromatography on silica gel, eluting with hexane/ethyl acetate (90:10
increasing to 25:75) to give the title compound as an amber oil (32.2g). ¹H NMR (CDCl₃) δ 7.53-7.55 (2H, m), 7.19-7.35 (3H, m), 5.56 (1H, s), 4.27 (2H, s), 3.99-4.03 (1H, m), 3.25 (1H, br s), 2.77-2.81 (1H, m), 2.77 (1H, br s), 2.12-2.20 (1H, m), 1.91-1.99 (2H, m), 1.77-1.83 (1H, m), and 1.39 (9H, s).

PREPARATION 8

2-Bromo-4-(trifluoromethoxy)phenol

To a cooled (0 °C) solution of 4-trifluoromethoxyphenol (35.6g, 0.2mol) in chloroform (280ml) was added dropwise a solution of bromine (32g, 0.2mol) in chloroform (50ml). The solution was stirred at 0°C for 1 hour and at room temperature for 2 hours. Dichloromethane (200ml) and water (400ml) were added and the organic phase was washed further with water(400ml), brine (200ml) and dried (MgSO₄). The solvent was removed and the residue was purified by distillation at reduced pressure to give the title compound. ¹H NMR (250MHz, CDCl₃) δ 7.38 (1H, d, J=2.1 Hz), 7.13 (1H, dd, J=9.1, 2.1 Hz), 7.03 (1H, d, J=9.1 Hz), and 5.53 (1H, s).

PREPARATION 9

2-Benzylxoy-5-(trifluoromethoxy)bromobenzene

2-Bromo-4-(trifluoromethoxy)phenol (Preparation 8; 5g, 20mmol) was dissolved in N,N-dimethylformamide (60ml), and potassium carbonate (5.4g, 40mmol) was added, followed by benzyl bromide (3.5ml, 30mmol), and the reaction was stirred at ambient temperature for 15 hours. The reaction was diluted with water (150ml) and extracted into ethyl acetate (3x60ml). The combined organic fractions were washed with water (100ml), brine (100ml), dried (MgSO₄) and evaporated in vacuo. Purification on silica, eluting with 2% and 5% ethyl acetate in hexane gave the title compound as a clear oil (6.7g, 96%). ¹H NMR (250MHz, CDCl₃) δ 5.47 (2H, s), 7.23 (1H, d, J=9 Hz), 7.43 (1H, dd J=8.2, 2.9 Hz), and 7.75 (6H, m).
PREPARATION 10

\(Z-(2S,3R)-1-\text{tert}-\text{Butoxycarbonyl}-3-(3\text{-hydroxyprop-1-en-1-yl})-2-\text{phenylpiperidin}-3\text{-ol}\)

5 Palladium on calcium carbonate, poisoned with lead (Lindlar catalyst, 2g) was added to a solution of \((2S,3R)-1-\text{tert}-\text{butoxycarbonyl}-3-(3\text{-hydroxypropyn-1yl})-2\text{-phenylpiperidin}-3\text{-ol}\) (Preparation 7; 32g, 96.6mmol) in ethyl acetate (300ml) and the mixture was stirred under hydrogen (1 atmosphere) for 4 hours. The mixture was filtered and the solvent was evaporated under reduced pressure to give the title compound as an oil (32g, 100%). \(^1H\) NMR (360MHz, CDCl3) \(\delta\) 7.42 (2H, d, \(J=7.6\) Hz), 7.35-7.25 (3H, m), 5.83 (1H, d, \(J=12.3\) Hz), 5.68 (1H, dt, \(J=12.3, 6.0\) Hz), 5.06 (1H, s), 4.27 (1H, m), 4.12 (2H, m), 3.32 (1H, m), 3.13 (1H, s), 2.28 (1H, t, \(J=5.9\) Hz), 2.02 (1H, m), 1.92-1.78 (3H, m), and 1.32 (9H, s). m/z (ES\(^+\)) 334 (M+1).

PREPARATION 11

\((5R,6S)-6\text{-Phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene}\)

Diethylazodicarboxylate (18.2ml, 115mmol) in THF (100ml) was added dropwise to a solution of \(Z-(2S,3R)-1-\text{tert}-\text{butoxycarbonyl}-3-(3\text{-hydroxyprop-1-en-1-yl})-2\text{-phenylpiperidin}-3\text{-ol}\) (Preparation 10; 32g, 96mmol) and triphenylphosphine (30.2g, 115mmol) in THF (700ml). The mixture was stirred at 0°C for 30 minutes then at room temperature for 1.5 hours. The solvent was evaporated under reduced pressure and the residue was purified by flash column chromatography on silica gel, eluting with hexane/ethyl acetate (95:5 increasing to 80:20) to give the title compound as a colorless solid (23.4g, 77%). \(^1H\) NMR (CDCl3) \(\delta\) 7.45 (2H, d, \(J=7.4\) Hz), 7.27 (2H, t, \(J=7.4\) Hz), 7.20 (1H, t, \(J=7.4\) Hz), 6.03 (1H, dt, \(J=6.1, 2.0\) Hz), 5.68 (1H, dt, \(J=6.1, 2.0\) Hz), 5.06 (1H, s), 4.61 (1H, dt, \(J=13.1, 2.0\) Hz), 4.32 (1H, dt, \(J=13.1, 2.0\) Hz), 4.08 (1H, m), 3.05 (1H, m), 2.05 (1H, m), 1.75 (3H, m), and 1.37 (9H, s). m/z (ES\(^+\)) 316 (M+1).
PREPARATION 12

2-Benzylxyloxy-5-(trifluoromethoxy)benzene

Benzyl bromide (66.17ml, 95.35g, 0.56mol) was added to a mixture of 4-(trifluoromethoxy)phenol (90.26g, 0.51mol) and potassium carbonate (140.97g, 1.2mol) in dimethylformamide (160ml) and the mixture was stirred at room temperature for 72 hours. The mixture was poured into water (1.5 l) and extracted with ethyl acetate (3x500ml). The combined organic fractions were washed with aqueous sodium carbonate (saturated, 500ml), dried (MgSO₄) and the solvent was evaporated under reduced pressure to give the title compound as a colorless solid (133.5g, 99%). ¹H NMR (360MHz, CDCl₃) δ 7.39 (5H, m), 7.14 (2H, d, J=9.0 Hz), 6.95 (2H, d, J=9.0 Hz), and 5.05 (2H, s).

PREPARATION 13

2-Benzylxyloxy-5-(trifluoromethoxy)iodobenzene

Iodine (71.96g, 0.28mol) in chloroform was added dropwise to a mixture of 2-benzylxyloxy-5-(trifluoromethoxy)benzene (Preparation 12, 73.06g, 0.27mol) and silver trifluoroacetate (71.57g, 0.32mol) in dichloromethane and the mixture was stirred at room temperature for 18 hours. The mixture was filtered through celite, washed with aqueous sodium thiosulfate (5%, 2x2 l), dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/ethyl acetate, to give the title compound as a colorless oil (108.03g), containing 11% unreacted 2-benzylxyloxy-5-(trifluoromethoxy)iodobenzene. ¹H NMR (360MHz, CDCl₃) δ 7.67 (1H, d, J=2.8 Hz), 7.40 (5H, m), 7.16 (1H, dd, J=8.9, 2.8 Hz), 6.82 (1H, d, J=8.9 Hz), and 5.14 (2H, s).
PREPARATION 14

\((5R,6S)-3-(2\text{-Benzylxy-5-}(\text{trifluoromethoxy})\text{phenyl})-6\text{-phenyl-1-oxa-7-}(\text{tert-}
\text{butoxycarbonyl})\text{aza-spiro[4.5]dec-3-ene}\)

\((5R,6S)-3\text{-Trimethylstannyl-6-phenyl-1-oxa-7-}(\text{tert-}
\text{butoxycarbonyl})\text{aza-spiro[4.5]dec-3-ene}\) (Preparation 6; 6.43mmol), lithium chloride (0.163g), benzyloxy-5-(trifluoromethoxy)phenol (Preparation 9;
7.7mmol) in toluene (25ml) was degassed before addition of triphenylphosphine palladium (0) (0.37g). The solution was degassed
thoroughly before heating to 110°C for 14 hours. The solution was
partitioned between water and ethyl acetate and the dried organic phase
was purified by chromatography on a column containing silica gel (eluting
with hexane containing increasing proportions of ethyl acetate between 0%
to 4%) to give the title compound. \(^1\)H NMR (360MHz, CDCl\(_3\)) \(\delta\) 1.33 (9H, s), 1.65 (1H, m), 1.76 (2H, m), 2.08 (1H, m), 3.11 (1H, m), 4.08 (1H, m),
4.60 (1H, dd, \(J=12.2\) Hz, \(J=2\) Hz), 4.92 (1H, dd, \(J=12.1\) Hz, \(J=1.8\) Hz), 5.08
(1H, s), 5.1 (2H, q, \(J=11.5\) Hz), 6.65 (1H, s), 6.94 (2H, d, \(J=8.9\) Hz), 7.08
(1H, d, \(J=9\) Hz), 7.18 (2H, t, \(J=8.1\) Hz), 7.25 (3H, m), 7.38 (5H, m).

PREPARATION 15

\((3S,5R,6S)-3-(2\text{-Hydroxy-5-}(\text{trifluoromethoxy})\text{phenyl})-6\text{-phenyl-1-oxa-7-}
(\text{tert-butoxycarbonyl})\text{aza-spiro[4.5]decane}\)

\((5R,6S)-3-(2\text{-Benzylxy-5-}(\text{trifluoromethoxy})\text{phenyl})-6\text{-phenyl-1-oxa-}
7-(\text{tert-butoxycarbonyl})\text{aza-spiro[4.5]dec-3-ene}\) (Preparation 14) (3.88g) was
dissolved in ethyl acetate (15ml) and methanol (15ml). Palladium
hydroxide on carbon (1.00g) was added and the suspension was shaken
under a hydrogen atmosphere (50 psi) for 72 hours. The mixture was
filtered and the solvent was evaporated under reduced pressure. The
residue was purified by medium pressure chromatography on silica gel,
eluting with hexane/ethyl acetate (75:25) to give \((3R,5R,6S)-3-(2\text{-hydroxy-}
5-(\text{trifluoromethoxy})\text{phenyl})-6\text{-phenyl-1-oxa-7-}(\text{tert-butoxycarbonyl})\text{aza-
spirol[4.5]decane}\) (191mg). \(^1\)H NMR (250MHz, CDCl\(_3\)) \(\delta\) 7.70 (2H, d, \(J=7.3\)

Hz), 7.33 (2H, t, J=7.3 Hz), 7.26 (1H, d, J=7.3 Hz), 7.05 (1H, br s), 6.96 (2H, m), 6.82 (1H, d, J=9.4 Hz), 5.43 (1H, s), 4.27 (1H, m), 4.01 (1H, m), 3.95 (1H, m), 3.73 (1H, m), 2.73 (2H, m), 2.33 (1H, m), 1.87-1.58 (4H, m); and 1.50 (9H, s) and 3S,5R,6S)-3-(2-hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane (2.3g), 1H NMR (360MHz, CDCl₃) δ 1.38 (9H, s), 1.73 (2H, m), 1.81 (1H, m), 2.18 (2H, m), 2.50 (1H, m), 2.81 (1H, m), 3.62 (1H, t, J=7.2 Hz), 3.92 (1H, m), 3.98 (1H, d, J=13.2 Hz), 4.23 (1H, m), 5.33 (1H, s), 6.75 (1H, d, J=8.5 Hz), 6.94 (2H, m), 7.25 (1H, m), 7.31 (2H, m), and 7.55 (2H, d, J=7.8 Hz).

**PREPARATION 16**

(3R,5R,6S)-3-(2-Benzyl oxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

A mixture of 2-benzyl oxy-5-(trifluoromethoxy)iodobenzene (Preparation 13, 21.8g, 55.2mmol), (5R,6S)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]dec-3-ene (Preparation 11, 7.0g, 22.1mmol), tetra-n-butylammonium chloride (6.18g, 22.2mmol), lithium chloride (9.35g, 0.22mol) and potassium formate (5.64g, 67.0mmol) in dimethylformamide (100ml) was degassed with a firestone valve (5 x). Palladium acetate (491mg, 2.2mmol) was added and the mixture was degassed with a firestone valve (5 x). The mixture was stirred at 60°C for 15 hours, then further 2-benzyl oxy-5-(trifluoromethoxy)iodobenzene (Preparation 13, 4.32g, 11.0mmol), potassium formate (2.78g, 33.5mmol) and palladium acetate (260mg, 1.1mmol) were added. The mixture was stirred at 60°C for 22 hours, cooled and filtered. The solvent was evaporated under reduced pressure, water (600ml) was added and the mixture was extracted with ethyl acetate (2x300ml). The combined organic fractions were washed with brine (300ml), dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/dichloromethane (75:25 increasing to 0:100) then
dichloromethane/ethyl acetate (95:5), to give the title compound (9.42g, 73%). 1H NMR (360MHz, CDCl3) δ 7.56 (2H, d, J=7.7 Hz), 7.40-7.20 (8H, m), 7.14 (1H, d, J=2.0 Hz), 7.00 (1H, dd, J=8.9, 2.0 Hz), 6.88 (1H, d, J=8.9 Hz), 5.30 (1H, s), 5.08 (2H, s), 4.27 (1H, m), 3.97 (1H, m), 3.87 (2H, m), 2.78 (1H, m), 2.56 (1H, m), 2.15 (1H, m), 1.96 (1H, m), 1.67 (3H, m), and 1.42 (9H, s).

PREPARATION 17


Palladium on carbon (10%, 0.59g) was added to a solution of (3R,5R,6S)-3-(2-benzoxyl-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 16, 6.10g, 10.5mmol) in methanol-water (99:1, 200ml) and the mixture was stirred under hydrogen (50 psi.) for 72 hours. The mixture was filtered, washing with ethanol, and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with dichloromethane/ethyl acetate (99:1 increasing to 90:10) to give the title compound. 1H NMR (360MHz, CDCl3) δ 7.70 (2H, d, J=7.3 Hz), 7.33 (2H, t, J=7.3 Hz), 7.26 (1H, d, J=7.3 Hz), 7.05 (1H, br s), 6.96 (2H, m), 6.82 (1H, d, J=9.4 Hz), 5.43 (1H, s), 4.27 (1H, m), 4.01 (1H, m), 3.95 (1H, m), 3.73 (1H, m), 2.73 (2H, m), 2.33 (1H, m), 1.87-1.58 (4H, m), and 1.50 (9H, s).

PREPARATION 18

(3S,5R,6S)-3-[2-(1-Phenylthiocyprop-1-yl)oxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

(3S,5R,6S)-3-(2-Hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 15) (290mg, 0.59mmol) was dissolved in toluene (5ml) and silver carbonate (179mg,
0.65mmol) was added in one portion. (1-Iodocyclopent-1-yl)phenylsulfide (Cohen T. and Matz J. R., J. Am. Chem. Soc. 1980, 102, 6902) (180mg, 0.65mmol) was then added over one minute at room temperature. The mixture was stirred at 55°C for 4 hours, then further portions of silver carbonate (179mg, 0.65mmol) and (1-Iodocyclopent-1-yl)phenylsulfide (180mg, 0.65mmol) were added. The mixture was stirred at 55°C for a further 3 hours, cooled, filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with hexane/ethyl acetate (90:10 increasing to 80:20) to give the title compound as a colourless oil (120mg, 32%). 

\[ ^1H \text{NMR} \]

(250MHz, CDCl3) δ 7.55-7.44 (4H, m), 7.36-7.23 (7H, m), 7.13-7.02 (2H, m), 5.16 (1H, br s), 4.09 (1H, t, J=6 Hz), 4.03-3.92 (1H, m), 3.67-3.49 (2H, m), 2.94-2.79 (1H, m), 2.26 (1H, dd, J=7.9, 12.9 Hz), 2.15-2.01 (2H, m), 1.76-1.59 (3H, m), 1.53-1.45 (4H, m), and 1.36 (9H, s). m/z (ES⁺) 642 (M+1).

**PREPARATION 19**

(3R,5R,6S)-3-[2-(1-Phenylthiocyclopent-1-yl)oxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decan

Prepared from (3R,5R,6S)-3-(2-hydroxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 17) according to the method of Preparation 18. \[ ^1H \text{NMR} \]

(360MHz, CDCl3) δ 7.57 (2H, app. d, J=7.6 Hz), 7.45 (2H, app. d, J=7.7 Hz), 7.36-7.19 (7H, m), 7.16-7.06 (2H, m), 5.28 (1H, br s), 4.13 (1H, app. t, J=7.8 Hz), 3.96 (1H, br. d, J=13 Hz), 3.80-3.60 (2H, m), 2.79 (1H, br. t, J=13 Hz), 2.50 (1H, dd, J=13, 7.9 Hz), 2.17 (1H, dt, J=13, 4.6 Hz), 1.80 (1H, dd, J=12, 9.8 Hz), 1.75-1.38 (7H, m), and 1.44 (9H, s). m/z (ES⁺) 642 (M+1).
PREPARATION 20

(3S,5R,6S)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

Naphthalene (120mg, 0.936mmol) was dissolved in THF (1.5ml) under nitrogen and freshly cut lithium metal (7.0mg, 0.94mmol) was added. The mixture was then sonicated at room temperature for 20 minutes to produce a dark green solution of lithium naphthalenide. This solution was cooled to -78 °C, then (3S,5R,6S)-3-[2-(1-phenylthiocyloprop-1-yl)oxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane (Preparation 18) (120mg, 0.187mmol) in THF (0.5ml) was added over 1 minute. The reaction mixture was stirred for 30 minutes, then water (5ml) and ether (10ml) were added. The layers were separated and the aqueous layer was extracted with ether (10ml). The combined organic fractions were dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with hexane/ethyl acetate (90:10 increasing to 80:20) to give the title compound as a colourless oil (58.6mg, 59%). ¹H NMR (250MHz, CDCl₃) δ 7.58-7.52 (2H, m), 7.36-7.17 (4H, m), 7.10-7.01 (2H, m), 5.18 (1H, br s), 4.20 (1H, t, J=6.7 Hz), 4.05-3.95 (1H, m), 3.76-3.55 (3H, m), 2.92-2.79 (1H, m), 2.37 (1H, dd, J=12.9, 7.8 Hz), 2.18-2.06 (2H, m), 1.80-1.67 (3H, m), 1.38 (9H, s), and 0.86-0.73 (4H, m). m/z (ES⁺) 534 (M+1).

PREPARATION 21

(3R,5R,6S)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane

Naphthalene (120mg, 0.936mmol) was dissolved in THF (1.5ml) under nitrogen and freshly cut lithium metal (7.0mg, 0.94mmol) was added. The mixture was then sonicated at room temperature for 20 minutes to produce a dark green solution of lithium naphthalenide. A solution of (3R,5R,6S)-3-[2-(1-phenylthiocyloprop-1-yl)oxy-5-
(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-
spiro[4.5]decane (Preparation 19, 135mg, 0.21mmol) in THF (2ml) under
nitrogen was cooled to -78°C and the solution of lithium naphthalenide in
THF was added dropwise until the intense green colour persisted. The
reaction was then stirred for one minute, water (5ml) was added and the
mixture was warmed to room temperature. Ether (10ml) was added and
the layers were separated. The aqueous phase was extracted with a
further portion of ether (10ml) and the combined organic phases were
dried (MgSO₄) and the solvent was evaporated under reduced pressure.
The residue was purified by column chromatography on silica gel, eluting
with hexane/ethyl acetate (50:50) to give the title compound as a colourless
oil (87mg, 78%). ¹H NMR (360MHz, CDCl₃) δ 7.59 (2H, app. d, J=7.6 Hz),
7.32 (2H, app. t, J=7.6 Hz), 7.27-7.18 (2H, m), 7.11-7.03 (2H, m), 5.32 (1H,
br s), 4.29-4.21 (1H, m), 3.97 (1H, br. d, J=13 Hz), 3.83-3.68 (3H, m), 2.76
(1H, dt, J=13, 4.1 Hz), 2.55 (1H, dd, J=13, 7.2 Hz), 2.22 (1H, dt, J=12, 5.2
Hz), 1.85 (1H, dd, J=13, 9.9 Hz), 1.80-1.63 (3H, m), 1.46 (9H, s), and 0.82-
0.76 (4H, m). m/z (ES⁺) 534 (M+1).

**COMPOUND A**

(3S,5R,6S)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-
7-aza-spiro[4.5]decane Hydrochloride

Trifluoroacetic acid (2.5ml) was added dropwise to a stirred, cooled
0°C solution of (3S,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-
6-phenyl-1-oxa-7-(tert-butoxycarbonyl)aza-spiro[4.5]decane (Preparation
20; 492mg, 0.92mmol) in dichloromethane (25ml) and the mixture was
stirred at room temperature for 3 hours. The mixture was poured into
water (50ml), the pH was adjusted to 10.0 with aqueous sodium hydroxide
(4M) and the mixture was extracted with dichloromethane (3x50ml). The
combined organic fractions were dried (MgSO₄) and the solvent was
everaged under reduced pressure. The residue was purified by flash
column chromatography on silica gel, eluting with
dichloromethane/methanol/ammonia (aq.) (96:4:0.4 increasing to 94:6:0.6). The residue was dissolved in ethanol (20ml), cooled in ice and ethereal hydrogen chloride (1M, 1.8ml, 1.8mmol) was added dropwise. The mixture was stirred at 0°C for 5 minutes, then the solvent was evaporated under reduced pressure. The residue was crystallized from ether (20ml)/ethanol (0.5ml) and the solid was collected and dried in vacuo to give the title compound as a colorless solid (354mg, 89%). m.p. 214-216 °C, 1H NMR (500MHz, CD3OD) δ 7.59 (2H, m), 7.52 (3H, m), 7.26 (1H, d, J=8.9 Hz), 7.03 (1H, dd, J=8.9, 2.2 Hz), 6.20 (1H, d, J=2.2 Hz), 4.85 (2H, br s), 4.43 (1H, s), 4.19 (1H, t, J=8.0 Hz), 3.87 (1H, quin, J=8.0 Hz), 3.76 (1H, m), 3.44 (1H, m), 3.25 (2H, m) 2.29-1.78 (6H, m), 0.80 (2H, m), and 0.66 (2H, m). m/z (ES+) 434 (M+1). Found: C, 61.41; H, 5.51; N, 3.08. C24H26F3NO3.HCl requires: C, 61.34; H, 5.79; N, 2.98%.

**COMPOUND B**

(3R,5R,6S)-3-[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spiro[4.5]decane

Prepared from the compound of Preparation 21 according to the method used for Compound A. 1H NMR (360MHz, CDCl3) δ 7.50-7.42 (2H, m), 7.36-7.26 (3H, m), 7.03 (1H, d, J=8.9 Hz), 6.95 (1H, br. d, J=8.9 Hz), 6.81 (1H, br s), 3.92 (1H, t, J=7.4 Hz), 3.62-3.53 (2H, m), 3.50 (1H, s), 3.20 (1H, dd, J=12, 4.2 Hz), 2.77 (1H, dt, J=12, 2.8 Hz), 2.30-1.93 (4H, m), 1.87 (1H, br s), 1.71-1.49 (3H, m), 0.76-0.65 (2H, m), and 0.65-0.54 (2H, m). m/z (ES+) 434 (M+1).

A further compound and diastereomers thereof of use in the present invention may be prepared according to the following method:

**DESCRIPTION 1**

2-(1-Phenylthiocycloprop-1-yloxy-5-(trifluoromethoxy)benzaldehyde

Silver carbonate (1.2 g, 4.34 mmol) was added to a solution of 2-hydroxy-5-(trifluoromethoxy)benzaldehyde (0.5 g, 2.43 mmol) and
(1-iodocycloprop-1-yl)phenylsulfide (Cohen T. and Matz J. R., J. Am. Chem. Soc. 1980, 102, 6902) (1.2 g, 4.34 mmol) in toluene (30 mL) and the mixture was stirred at 40 °C overnight. The mixture was cooled, diluted with ethyl acetate and filtered, washing well with ethyl acetate. The mixture was washed with aqueous sodium hydroxide, dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et₂O (95:5), to give the title compound as a yellow oil (191 mg, 27%). ¹H NMR (360MHz, CDCl₃) δ 1.51-1.56 (2H, m), 1.44-1.48 (2H, m), 7.25-7.35 (7H, m), 7.69 (1H, d, J 2.0 Hz), and 10.26 (1H, s).

**DESCRIPTION 2**

2-Cyclopropoxy-5-(trifluoromethoxy)benzaldehyde

Freshly cut lithium metal (97 mg, 13.9 mmol) was added to a solution of naphthalene (1.77 g, 13.9 mmol) in THF (20 mL) and the mixture was sonicated at room temperature for 30 min. to produce a dark green solution of lithium naphthalenide. A solution of 2-(1-phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)benzaldehyde (Description 1, 96 mg, 0.27 mmol) in THF (2 mL) was cooled to -78 °C and the solution of lithium naphthalenide in THF (2 mL) was added dropwise until the intense green colour persisted. The reaction was then stirred for 5 min., water (6 mL) was added and the mixture was warmed to room temperature. The mixture was extracted with ethyl acetate, the combined organic fractions were dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et₂O (80:20), to give to give the title compound as a colourless oil (4 mg, 6%). ¹H NMR (360MHz, CDCl₃) δ 0.86 (4H, m), 3.82-3.9 (1H, m), 7.42 (2H, m), 7.62 (1H, d, J 2.5 Hz), and 10.36 (1H, s).
DESCRIPTION 3

2-Nitro-4-(trifluoromethoxy)phenol

Iron(111) nitrate nonahydrate (1.97 g, 4.87 mmol) was added to a solution of 4-(trifluoromethoxy)phenol (2 g, 11.24 mmol) in ethanol (20 mL) and the mixture was heated under reflux overnight. The mixture was allowed to cool to room temperature, acidified to pH 1 with aqueous hydrochloric acid (1M) and extracted with ethyl acetate. The combined organic fractions were dried (MgSO₄), and the solvent was evaporated under reduced pressure. The residue was purified by short column chromatography on silica gel, eluting with hexane/EtOAc (70:30), to give the title compound as a yellow oil (2.25 g, 89%). ¹H NMR (360MHz, CDCl₃) δ 10.53 (1H, s), 8.01 (1H, d, J 3.0 Hz), 7.49 (1H, dd, J 9.1, 3.0 Hz), and 7.23 (1H, d, J 9.1 Hz).

DESCRIPTION 4

2-(1-Phenylthiocycloprop-1-yl)oxy-5-(trifluoromethoxy)nitrobenzene

Prepared from the compound of Description 3 according to the method of Description 1. ¹H NMR (360MHz, CDCl₃) δ 7.73 (1H, d, J 2.7 Hz), 7.58 (1H, d, J 9.2 Hz), 7.50-7.24 (6H, m), 1.57-1.53 (2H, m), and 1.44-1.40 (2H, m).

DESCRIPTION 5

2-Cyclopropoxy-5-(trifluoromethoxy)benzeneamine

Prepared from the compound of Description 4 according to the method of Description 2. ¹H NMR (360MHz, CDCl₃) δ 7.06 (1H, dd, J 2.8, 6.7 Hz), 6.56 (2H, m), 3.83 (2H, br s), 3.74 (1H, m), and 0.79 (4H, m). m/z (ES⁺) 234 (M+1).
DESCRIPTION 6

2-(1-Phenylthiocyprop-1-yl)oxy-5-(trifluoromethoxy)benzeneamine

Iron powder (13.5 g, 241 mmol) was added to a suspension of 2-(1-phenylthiocyprop-1-yl)oxy-5-(trifluoromethoxy)nitrobenzene (Description 4, 11.27 g, 30.1 mmol) in water (300 mL) and acetic acid (75 mL) and the mixture was stirred at 80 °C overnight. The mixture was cooled and filtered through celite, washing with ether. The filtrate was extracted with ether, the combined organic fractions were washed with aqueous sodium hydroxide (1M), dried (MgSO₄), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et₂O (90:10 increasing to 80:20), to give the title compound as a yellow solid (8 g, 78%). ¹H NMR (360MHz, CDCl₃) δ 7.48 (2H, m), 7.34-7.23 (3H, m), 7.15 (1H, d, J 8.74 Hz), 6.60-6.56 (2H, m), 3.78 (2H, br s), 1.49-1.46 (2H, m), and 1.39-1.35 (2H, m).

DESCRIPTION 7

2-Cyclopropoxy-5-(trifluoromethoxy)benzeneamine

Prepared from the compound of Description 6 according to the method of Description 2. ¹H NMR (360MHz, CDCl₃) δ 7.06 (1H, dd, J 2.8, 6.7 Hz), 6.56 (2H, m), 3.83 (2H, br s), 3.74 (1H, m), and 0.79 (4H, m). m/z (ES⁺) 234 (M+1).

DESCRIPTION 8

2-Cyclopropoxy-5-(trifluoromethoxy)iodobenzene

An ice-cooled solution of sodium nitrite (3.55 g, 51 mmol) in water (10 mL) was added dropwise to a stirred, cooled (0 °C) solution of 2-cyclopropoxy-5-(trifluoromethoxy)benzeneamine (Description 7, 4.8 g, 20.6 mmol) in aqueous hydrochloric acid (5M, 300 mL), maintaining the internal temperature at 0 °C. The mixture was stirred at 0 °C for 30 min., then potassium iodide (8.55 g, 51.5 mmol) in water (10 mL) was added
dropwise, maintaining the internal temperature at 0 °C. The mixture was stirred at 0 °C for 30 min., then allowed to warm up to room temperature and stirred until nitrogen evolution ceased. The mixture was extracted with ether, the organic fraction was washed with aqueous sodium thiosulfate (10%), dried (MgSO₄), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et₂O (98:2 increasing to 95:5), to give the title compound as a colourless oil (6.23 g, 88%). ¹H NMR (360MHz, CDCl₃) δ 7.62 (1H, d, J 2.4 Hz), 7.20 (1H, dd, J 9.1, 2.4 Hz), 7.15 (1H, d, J 9.1 Hz), 3.80 (1H, m), and 0.83 (4H, m).

DESCRIPTION 9

2-Cyclopropoxy-5-(trifluoromethoxy)benzaldehyde

A solution of 2-cyclopropoxy-5-(trifluoromethoxy)iodobenzene (Description 8, 0.344 g, 1 mmol) in toluene (2.5 mL) was degassed with bubbling nitrogen for 10 min. Tetrakis(triphenylphosphine)palladium (0) (15 mg) was added, the mixture was degassed with bubbling nitrogen for a further 5 min., then carbon monoxide was bubbled through the mixture for 10 min. The mixture was warmed to 50 °C and a solution of tributyl tin hydride (0.3 mL, 1.1 mmol) in toluene (5 mL) was added at a rate of 2 mL/h. via a syringe pump, maintaining carbon monoxide bubbling throughout. The mixture was cooled, diluted with ether (20 mL) and aqueous potassium fluoride solution (50%) was added. The mixture was stirred at room temperature overnight, filtered and the layers were separated. The organic layer was dried (MgSO₄), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/Et₂O (80:20), to give the title compound as a colourless oil. ¹H NMR (360MHz, CDCl₃) δ 0.86 (4H, m), 3.82-3.9 (1H, m), 7.42 (2H, m), 7.62 (1H, d, J 2.5 Hz), and 10.36 (1H, s).
DESCRIPTION 10

(±)-(2RS)-1-tert-Butoxycarbonyl-2-phenylpiperidin-3-one

Dimethyl sulfoxide (32.0 mL, 35.3 g, 0.45 mol) in dichloromethane (100 mL) was added dropwise to a cooled (-70 °C) solution of oxalyl chloride (18.7 mL, 27.5 g, 0.22 mol) in dichloromethane (1000 mL). The mixture was stirred at -70 °C for 15 min., then (2S,3S)-1-tert-butoxycarbonyl-3-hydroxy-2-phenylpiperidine (prepared by the method described in European Patent Specification number 0 528 495-A; 50 g, 0.18 mol) in dichloromethane (150 mL) was added dropwise. The mixture was stirred at -70 °C for 1 h., then triethylamine (125.8 mL, 91.3 g, 0.9 mol) was added slowly. The mixture was stirred at room temperature for 1 h., water (250 mL) and aqueous sodium hydrogen carbonate (saturated, 250 mL) were added and the mixture was stirred at room temperature overnight. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 300 mL). The combined organic fractions were washed with brine, dried (MgSO₄) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/EtOAc (90:10), to give the title compound as a yellow oil (45.0 g, 91%). ¹H NMR (250MHz, CDCl₃) δ 7.5-7.3 (5H, m), 5.8 (1H, br s), 4.2 (1H, br s), 3.4 (1H, m), 2.6 (2H, m), 2.0 (2H, m), and 1.54 (9H, s).

DESCRIPTION 11

(±)-(2R3R,2S3S)-1-(tert-Butoxycarbonyl)-2-phenylpiperidin-3-amine

A solution of hydroxylamine hydrochloride (17 g, 0.24 mol) and sodium acetate (55.67 g, 0.41 mol) in water (150 mL) was added to a solution of (±)-(2RS)-1-tert-butoxycarbonyl-2-phenylpiperidin-3-one (Description 10, 45 g, 0.16 mol) in ethanol (300 mL) and the mixture was stirred at room temperature for 1 h. The solvent was evaporated under reduced pressure, water was added and the mixture was extracted with ethyl acetate. The organic fraction was washed with brine, dried (MgSO₄)
and the solvent was evaporated under reduced pressure. The residue was
dissolved in ethanol (400 mL) and Raney nickel (50 g) was added. The
mixture was shaken under hydrogen (40 psi) overnight, filtered and the
solvent was evaporated under reduced pressure. The residue was purified
by flash column chromatography on silica gel, eluting with CH₂Cl₂/MeOH
(100:0 increasing to 85:15), to give the title compound as a colorless oil
(10.9 g, 24%). ¹H NMR (360MHz, CDCl₃) δ 7.43 (2H, d, J 7.0 Hz), 7.30 (3H,
m), 5.19 (1H, d, J 6.2 Hz), 4.00 (1H, m), 3.17 (2H, m), 1.90-1.64 (4H, m),
1.36 (9H, s), and 1.26 (2H, br s).

COMPOUND C

(±)-(2R3R,2S3S)-N-[[2-Cyclopropoxy-5-(trifluoromethoxy)phenyl]methyl]-2
-phenylpiperidin-3-amine Dihydrochloride

2-Cyclopropoxy-5-(trifluoromethoxy)benzaldehyde (Description 9, 55
mg, 0.21 mmol) was added to (±)-(2R3R,2S3S)-1-(tert-butoxycarbonyl)-2-
phenylpiperidin-3-amine (Description 11, 58 mg, 0.21 mmol), citric acid
(89 mg, 0.42 mmol) and 3Å molecular sieves in dry methanol (5 mL) and
the mixture was stirred at room temperature for 1.5 h. Sodium
borohydride (30 mg) was added and the mixture was stirred at room
temperature for 2 h. Ethyl acetate was added and the mixture was washed
with aqueous hydrochloric acid (0.1M, 2 x 25 mL) and brine (25 mL), dried
(MgSO₄) and the solvent was evaporated under reduced pressure. The
residue was dissolved in dichloromethane (3 mL), cooled to 0 °C and
trifluoroacetic acid (2 mL) was added slowly. The mixture was stirred at
room temperature for 1 h., the solvent was evaporated under reduced
pressure and ethyl acetate was added. The mixture was washed with
aqueous sodium hydrogen carbonate (saturated, 2 x 25 mL) and brine (25
mL), dried (MgSO₄) and the solvent was evaporated under reduced
pressure. The residue was purified by flash column chromatography on
silica gel, eluting with CH₂Cl₂/MeOH/NH₃(Aq.) (96:4:0.4). The residue was
dissolved in ethanol (2 mL), cooled in ice and ethereal hydrogen chloride
(1M, 0.24 mL, 0.24 mmol) was added. The solvent was evaporated under reduced pressure and the residue was recrystallised from ethanol to give the title compound as a colorless solid (20 mg, 20%). m.p. 169-171 °C. \(^1\)H NMR (400MHz, CD\(_3\)OD) δ 0.64 (1H, m), 0.80 (3H, m), 1.99 (1H, m), 2.24 (1H, m), 2.46 (2H, m), 3.30 (1H, m), 3.64 (1H, m), 3.75 (2H, m), 3.96 (1H, br s), 4.08 (1H, m), 4.95 (1H, s), 7.23 (1H, s), 7.31 (1H, d, J 9.0 Hz), 7.37 (1H, d, J 9.0 Hz), 7.54 (3H, m), and 7.67 (2H, m). m/z (ES\(^+\)) 407 (M+1).

Particularly preferred NK-1 receptor antagonists of use in the present invention are compounds which are potent NK-1 receptor antagonists, i.e. compounds with an NK-1 receptor affinity (IC\(_{50}\)) of less than 10nM, favourably less than 2nM and preferably less than 1nM.

The class of orally active, long acting, CNS-penetrant NK-1 receptor antagonists of use in the present invention is identified using a combination of the following assays:

ASSAY 1: NK-1 Receptor binding

NK-1 receptor binding assays are performed in intact Chinese hamster ovary (CHO) cells expressing the human NK-1 receptor using a modification of the assay conditions described by Cascieri \textit{et al}, \textit{J. Pharmacol. Exp. Ther.}, 1992, 42, 458. Typically the receptor is expressed at a level of 3x10\(^5\) receptors per cell. Cells are grown in monolayer culture, detached from the plate with enzyme-free dissociation solution (Speciality Media Inc.), and washed prior to use in the assay. \(^{125}\)I-Tyr\(^8\)-substance P (0.1nM, 2000Ci/mmole; New England Nuclear) is incubated in the presence or absence of test compounds (dissolved in 5\(\mu\)l dimethylsulphoxide, DMSO) with 5x10\(^4\) CHO cells. Ligand binding is performed in 0.25ml of 50mM Tris-HCl, pH7.5, containing 5mM MnCl\(_2\), 150mM NaCl, 0.02% bovine serum albumin (Sigma), 50\(\mu\)g/ml chymostatin (Peninsula), 0.1nM phenylmethylsulphonyl fluoride, 2\(\mu\)g/ml pepstatin, 2\(\mu\)g/ml leupeptin and 2.8\(\mu\)g/ml furoyl saccharine. The incubation proceeds at room temperature until equilibrium is achieved (>40 minutes) and the
receptor-ligand complex is harvested by filtration over GF/C filters pre-soaked in 0.1% polyethylenimine using a Tomtek 96-well harvester. Non-specific binding is determined using excess substance P (1μM) and represents <10% of total binding.

ASSAY 2: Gerbil Foot-Tapping

CNS-penetrant NK-1 receptor antagonists for use in the present invention can be identified by their ability to inhibit foot tapping in gerbils induced by anxiogenic agents (such as pentagastrin) or central infusion of NK-1 receptor agonists such as GR73632, or caused by aversive stimulation such as foot shock or single housing, based on the method of Rupniak & Williams, Eur. J. Pharmacol., 1994, 265, 179.

Male or female Mongolian gerbils (35-70g) are anaesthetised by inhalation of an isoflurane/oxygen mixture to permit exposure of the jugular vein in order to permit administration of test compounds or vehicle in an injection volume of 5ml/kg i.v. Alternatively, test compounds may be administered orally or by subcutaneous or intraperitoneal routes. A skin incision is then made in the midline of the scalp to expose the skull. An anxiogenic agent (e.g. pentagastrin) or a selective NK-1 receptor agonist (e.g. GR73632 (d Ala[1-Pro9,Me-Leu16]-substance P-(7-11)) is infused directly into the cerebral ventricles (e.g. 3pmol in 5μl i.c.v., depending on test substance) by vertical insertion of a cuffed 27 gauge needle to a depth of 4.5mm below bregma. The scalp incision is closed and the animal allowed to recover from anaesthesia in a clear perspex observation box (25cm x 20cm x 20cm). The duration and/or intensity of hind foot tapping is then recorded continuously for approximately 5 minutes. Alternatively, the ability of test compounds to inhibit foot tapping evoked by aversive stimulation, such as foot shock or single housing, may be studied using a similar method of quantification.
ASSAY 3: Ferret Emesis

Individually housed male ferrets (1.0 -2.5 kg) are dosed orally by gavage with test compound. Ten minutes later they are fed with approximately 100g of tinned cat food. At 60 minutes following oral dosing, cisplatin (10mg/kg) is given i.v. via a jugular vein catheter inserted under a brief period of halothane anaesthesia. The catheter is then removed, the jugular vein ligated and the skin incision closed. The ferrets recover rapidly from the anaesthetic and are mobile within 10-20 minutes. The animals are observed continuously during recovery from the anaesthetic and for 4 hours following the cisplatin injection, after which time the animals are killed humanely. The numbers of retches and vomits occurring during the 4 hours after cisplatin administration are recorded by trained observers.

ASSAY 4: Separation-Induced Vocalisation

Male and female guinea-pigs pups are housed in family groups with their mothers and littermates throughout the study. Experiments are commenced after weaning when the pups are 2 weeks old. Before entering an experiment, the pups are screened to ensure that a vigorous vocalisation response is reproducibly elicited following maternal separation. The pups are placed individually in an observation cage (55cm x 39cm x 19cm) in a room physically isolated from the home cage for 15 minutes and the duration of vocalisation during this baseline period is recorded. Only animals which vocalise for longer than 5 minutes are employed for drug challenge studies (approximately 50% of available pups may fail to reach this criterion). On test days each pup receives an oral dose or an s.c. or i.p. injection of test compound or vehicle and is then immediately returned to the home cage with its mother and siblings for 30 to 60 minutes (or for up to 4 hours following an oral dose, dependant upon the oral pharmacokinetics of the test compound) before social isolation for 15 minutes as described above. The duration of vocalisation on drug
treatment days is expressed as a percentage of the pre-treatment baseline value for each animal. The same subjects are retested once weekly for up to 6 weeks. Between 6 and 8 animals receive each test compound at each dose tested.

As used herein, the term “CNS-penetrant” refers to NK-1 receptor antagonists which are able to inhibit NK-1 receptor antagonist-induced foot-tapping in the gerbil as hereinafter defined.

Essentially, hind foot-tapping in the gerbil induced by infusion of the NK-1 receptor agonist, GR73632 (d Ala[L-Pro9,Me-Leu10]-substance P-(7-11)), under anaesthesia, directly into the central ventricles is inhibited when a CNS-penetrant NK-1 receptor antagonist is administered intravenously immediately prior to GR73632 challenge, wherein hind foot-tapping over a period of five minutes following recovery from the anaesthesia is inhibited with an ID$_{50}$≤3mg/kg, and preferably with an ID$_{50}$≤1mg/kg.

In an alternative method, the NK-1 receptor antagonist is administered orally, 1 hour prior to GR73632 challenge, wherein the foot-tapping over a period of five minutes following recovery from anaesthesia is inhibited with an ID$_{50}$≤30mg/kg, and preferably with an ID$_{50}$≤10mg/kg.

CNS-penetrant NK-1 receptor antagonists of use in the present invention are also effective in the attenuation of separation-induced vocalisations by guinea-pig pups as hereinafter defined.

Essentially, a vocalisation response in guinea-pig pups is induced by isolation from their mothers and littermates, which response is attenuated when a CNS-penetrant NK-1 receptor antagonist is administered subcutaneously 30 minutes prior to isolation, wherein vocalisations during the first 15 minutes of isolation are attenuated with an ID$_{50}$≤20mg/kg, preferably with an ID$_{50}$≤10mg/kg, and especially with an ID$_{50}$≤5mg/kg.

In an alternative method, the NK-1 receptor antagonist is administered orally, 4 hours prior to isolation, wherein vocalisations during the first 15 minutes of isolation are attenuated with an
ID\textsubscript{50} \leq 20\text{mg/kg}, preferably with an ID\textsubscript{50} \leq 10\text{mg/kg}, and especially with an
ID\textsubscript{50} \leq 5\text{mg/kg}.

A suitable selection cascade for NK\textsubscript{1} antagonists of use according to
the present invention is as follows:

(i) Determine affinity for human NK\textsubscript{1} receptor in radioligand
binding studies (Assay 1); select compounds with IC\textsubscript{50} \leq 10\text{nM}, preferably
IC\textsubscript{50} \leq 2\text{nM}, especially IC\textsubscript{50} \leq 1\text{nM}.

(ii) Determine ability of compounds to penetrate CNS by their
ability to inhibit foot tapping in gerbils induced by central injection of an
NK\textsubscript{1} agonist (Assay 2); select compounds that inhibit foot tapping with
ID\textsubscript{50} \leq 3\text{mg/kg i.v.}, and preferably ID\textsubscript{50} \leq 1\text{mg/kg i.v.} when administered
immediately prior to central NK\textsubscript{1} agonist challenge, or ID\textsubscript{50} \leq 30\text{mg/kg p.o.},
and preferably ID\textsubscript{50} \leq 10\text{mg/kg p.o.} 1 hour prior to challenge.

(iii) Determine central duration of action of compounds in gerbil foot
tapping assay following intravenous administration 24 hours prior to
central NK\textsubscript{1} agonist challenge; select compounds showing \leq 25-fold loss of
potency compared with ID\textsubscript{50} determined in step (ii) above with the proviso
that ID\textsubscript{50} \leq 10\text{mg/kg i.v.}, and preferably \leq 5\text{mg/kg i.v.} after 24 hour
pre-treatment.

(iv) Determine oral bioavailability of compounds by
pharmacokinetic analysis, activity in gerbil foot tapping assay following
oral administration and/or by ability to inhibit cisplatin-induced emesis in
ferrets (Assay 3); select compounds with ID\textsubscript{90} \leq 3\text{mg/kg p.o.}, and preferably
ID\textsubscript{90} \leq 1\text{mg/kg p.o.}

Particularly preferred compounds of use in the present invention
are identified using steps (i) to (iv) followed by step (v):

(v) Determine activity of compounds in assays sensitive to
conventional antidepressant/anxiolytic drugs (inhibition of
pharmacologically evoked foot tapping in gerbils and/or inhibition of
distress vocalisations in guinea-pig pups (Assay 4)). Select compounds with $\text{ID}_{50} \leq 20\text{mg/kg}$, and preferably $\text{ID}_{50} \leq 10\text{mg/kg}$.

Yet further preferred compounds of use in the present invention may be selected from those compounds which satisfy the NK-1 receptor binding criteria of step (i) which, in addition, have $\leq 5$-fold shift in affinity when incubated in the presence of human serum albumin (HSA) to show non-specific protein binding.

One example of a NK-1 receptor antagonist of use in the present invention is the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)-ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine, the preparation of which is described in International Patent Specification No. WO 95/16679. In the aforementioned assays, this compound has the following activity:

- human NK-1 receptor binding: $\text{IC}_{50}=0.1\text{nM}$
- gerbil foot-tapping (5 mins.): $\text{ID}_{50}=0.36\text{mg/kg i.v.}$
- gerbil foot-tapping (24 hrs.): $\text{ID}_{50}=0.33\text{mg/kg i.v.}$
- ferret emesis: $\text{ID}_{90}<3\text{mg/kg p.o.}$
- guinea-pig vocalisation (4 hr. pre-treatment): $\text{ID}_{50}=0.73\text{mg/kg p.o.}$

The following example illustrates pharmaceutical compositions according to the invention.

**EXAMPLE 1 Tablets containing 50-300mg of NK-1 antagonist**

<table>
<thead>
<tr>
<th></th>
<th>Amount mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>NK-1 antagonist</td>
<td>50.0</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>80.0</td>
</tr>
<tr>
<td>Modified food corn starch</td>
<td>80.0</td>
</tr>
<tr>
<td>Lactose</td>
<td>189.5</td>
</tr>
<tr>
<td>Magnesium Stearate</td>
<td>0.5</td>
</tr>
</tbody>
</table>
The active ingredient, cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 50mg, 100mg and 300mg of the NK-1 receptor antagonist per tablet.
CLAIMS

1. Use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders.

2. Use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders in a patient who is non-responsive to heterocyclic antidepressants, SSRIs, serotonin agonists or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs, or for whom heterocyclic antidepressants, SSRIs, serotonin agonists or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs are contraindicated.

3. Use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of cognitive disorders in a patient who is non-responsive to antipsychotic agents, or for whom antipsychotic agents are contraindicated.

4. An oral pharmaceutical composition for the treatment of cognitive disorders which comprises an orally active, long acting, CNS-penetrant NK-1 receptor antagonist, together with a pharmaceutically acceptable carrier or excipient.

5. A method for the treatment or prevention of cognitive disorders, which method comprises the oral administration to a patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.
6. A method for the treatment or prevention of cognitive disorders in a patient who is non-responsive to heterocyclic antidepressants, SSRIs, serotonin agents or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs, or for whom heterocyclic antidepressants, SSRIs, serotonin agents or antagonists, mixed serotonin and norepinephrine selective reuptake inhibitors, dopamine reuptake inhibitors or MAOIs are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.

7. A method for the treatment or prevention of cognitive disorders in a patient who is non-responsive to antipsychotic agents, or for whom antipsychotic agents are contraindicated, which method comprises oral administration to the patient in need of such treatment of an effective amount of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist.

8. A use according to claim 1, 2 or 3, or a composition according to claim 4 or a method according to claim 5, 6 or 7 wherein the orally active, long acting, CNS-penetrant NK-1 receptor antagonist is selected from the classes of compounds described in EP-A-0577394, WO-A-9508549, WO-A-9518124, WO-A-9523798, WO-A-9605181 and International Patent Application No. PCT/GB97/01630.

9. A use according to claim 1, 2 or 3, or a composition according to claim 4 or a method according to claim 5, 6 or 7 wherein the orally active, long acting, CNS-penetrant NK-1 receptor antagonist is:

\[ 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine; \]
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;
2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(4-monophosphoryl-5-oxo-1H,1,2,4-triazolo)methyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(1-monophosphoryl-5-oxo-1H,1,2,4-triazolo)methyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(2-monophosphoryl-5-oxo-1H,1,2,4-triazolo)methyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxyphosphoryl-1H,1,2,4-triazolo)methyl)morpholine;
2-(S)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(1-monophosphoryl-5-oxo-4H-1,2,4-triazolo)methyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N,N-dimethylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;
(3S,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-1-oxa-7-aza-spiro[4.5]decane;
(3R,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-1-oxa-7-aza-spiro[4.5]decane;
(±)-(2R3R,2S3S)-N-[(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)methyl]-2-phenylpiperidin-3-amine;
or a pharmaceutically acceptable salt thereof.
10. A use according to claim 1, 2 or 3, or a composition according to claim 4 or a method according to claim 5, 6 or 7 wherein the cognitive disorders are selected from dementia, amnestic disorders and cognitive disorders not otherwise specified.

11. A use, composition or method according to claim 10 wherein the dementia is caused by degenerative disorders, lesions, trauma, infections, vascular disorders, toxins, anoxia, vitamin deficiency or endocrine disorders.

12. A use, composition or method according to claim 10 wherein the amnestic disorders are caused by: alcohol and other causes of thiamine deficiency; bilateral temporal lobe damage due to herpes simplex encephalitis and other limbic encephalitis, neuronal loss secondary to anoxia/hypoglycaemia/severe convulsions, and surgery; degenerative disorders; vascular disorders; or pathology around ventricle III.

13. A use according to claim 1, 2 or 3, or a composition according to claim 4 or a method according to claim 5, 6 or 7 wherein the cognitive disorders are due to cognitive impairment resulting from other medical conditions.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/535 A61K31/445

According to international Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>EP 0 670 309 A (JAPAN TOBACCO INC.) 6 September 1995 see whole document</td>
<td>1-7</td>
</tr>
<tr>
<td>Y</td>
<td>WO 96 05181 A (MERCK SHARP &amp; DOHME) 22 February 1996 cited in the application see page 16, line 16 - line 25; claims; examples</td>
<td>1-13</td>
</tr>
<tr>
<td>Y</td>
<td>WO 95 08549 A (GLAXO) 30 March 1995 cited in the application see page 11, line 8 - line 13; claims; examples</td>
<td>1-13</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C.

* Special categories of cited documents:
  *A* document defining the general state of the art which is not considered to be of particular relevance
  *E* earlier document but published on or after the international filing date
  *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  *O* document referring to an oral disclosure, use, exhibition or other means
  *P* document published prior to the international filing date but later than the priority date claimed

* later document published after the international filing date or priority date and not in conflict with the application but oiled to understand the principle or theory underlying the invention
*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*Y* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
* document member of the same patent family

Date of the actual completion of the international search

9 April 1998

Date of mailing of the international search report

30 04 98

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer
Helps, I
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>EP 0 577 394 A (MERCK &amp; CO.) 5 January 1994 cited in the application see page 19, line 34 - line 39; claims; examples</td>
<td>1-13</td>
</tr>
<tr>
<td>Y</td>
<td>WO 95 18124 A (MERCK SHARP &amp; DOHME ) 6 July 1995 cited in the application see page 30, line 24 - line 29; claims; examples</td>
<td>1-13</td>
</tr>
</tbody>
</table>
INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **X** Claims Nos.: 5-7  
   because they relate to subject matter not required to be searched by this Authority, namely:  
   Although claims 5-7 are drawn to a method of treatment of the human or animal body by therapy (Rule 39.1(iv) PCT) the search has been carried out based on the alleged effects of the compounds and compositions.

2. **☐** Claims Nos.:  
   because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. **☐** Claims Nos.:  
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. **☐** As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. **☐** As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. **☐** As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. **☐** No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  

Remark on Protest  

☐ The additional search fees were accompanied by the applicant's protest.  

☐ No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP 670309 A</td>
<td>06-09-95</td>
<td>US 5536737 A</td>
<td>16-07-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2149892 A</td>
<td>09-06-94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9412474 A</td>
<td>09-06-94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2618840 B</td>
<td>11-06-97</td>
</tr>
<tr>
<td>WO 9605181 A</td>
<td>22-02-96</td>
<td>AU 3185595 A</td>
<td>07-03-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2195972 A</td>
<td>22-02-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0777659 A</td>
<td>11-06-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9506757 A</td>
<td>03-04-96</td>
</tr>
<tr>
<td>WO 9508549 A</td>
<td>30-03-95</td>
<td>AP 495 A</td>
<td>28-05-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 681190 B</td>
<td>21-08-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 7697494 A</td>
<td>10-04-95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BG 100487 A</td>
<td>31-12-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1135218 A</td>
<td>06-11-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ 9600830 A</td>
<td>11-09-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0720609 A</td>
<td>10-07-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 961270 A</td>
<td>03-05-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HR 940575 A</td>
<td>28-02-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 75648 A</td>
<td>28-05-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 9505275 T</td>
<td>27-05-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 961156 A</td>
<td>21-05-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 273614 A</td>
<td>22-09-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 313619 A</td>
<td>08-07-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK 38396 A</td>
<td>05-02-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5703240 A</td>
<td>30-12-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9407291 A</td>
<td>31-05-95</td>
</tr>
<tr>
<td>EP 0577394 A</td>
<td>05-01-94</td>
<td>AU 4156893 A</td>
<td>06-01-94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4656193 A</td>
<td>24-01-94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BG 99274 A</td>
<td>30-04-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2699233 A</td>
<td>30-12-93</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1087902 A</td>
<td>15-06-94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ 9403330 A</td>
<td>13-09-95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 946133 A</td>
<td>28-12-94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HR 931003 A</td>
<td>28-02-95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 71809 A</td>
<td>28-02-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1L 106142 A</td>
<td>18-03-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2634372 B</td>
<td>23-07-97</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 6172178 A</td>
<td>21-06-94</td>
</tr>
</tbody>
</table>
## INTERNATIONAL SEARCH REPORT

**Information on patent family members**

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP 0577394 A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MX 9303888 A</td>
<td>31-03-94</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NO 945064 A</td>
<td>28-02-95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NZ 254476 A</td>
<td>25-09-96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SI 9300346 A</td>
<td>31-12-93</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SK 160094 A</td>
<td>11-07-95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WO 9400440 A</td>
<td>06-01-94</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US 5637699 A</td>
<td>10-06-97</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US 5719147 A</td>
<td>17-02-98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AU 4160893 A</td>
<td>06-01-94</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZA 9304624 A</td>
<td>20-06-94</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**WO 9518124 A**

<table>
<thead>
<tr>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>06-07-95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AU 685209 B</td>
<td>15-01-98</td>
<td></td>
</tr>
<tr>
<td>AU 1322395 A</td>
<td>17-07-95</td>
<td></td>
</tr>
<tr>
<td>BG 100644 A</td>
<td>31-03-97</td>
<td></td>
</tr>
<tr>
<td>BR 9408442 A</td>
<td>05-08-97</td>
<td></td>
</tr>
<tr>
<td>CA 2178219 A</td>
<td>06-07-95</td>
<td></td>
</tr>
<tr>
<td>CN 1139927 A</td>
<td>08-01-97</td>
<td></td>
</tr>
<tr>
<td>CZ 9601898 A</td>
<td>11-12-96</td>
<td></td>
</tr>
<tr>
<td>EP 0737192 A</td>
<td>16-10-96</td>
<td></td>
</tr>
<tr>
<td>HU 75872 A</td>
<td>28-05-97</td>
<td></td>
</tr>
<tr>
<td>JP 9507484 T</td>
<td>29-07-97</td>
<td></td>
</tr>
<tr>
<td>LV 11687 B</td>
<td>20-10-97</td>
<td></td>
</tr>
<tr>
<td>NO 962749 A</td>
<td>28-08-96</td>
<td></td>
</tr>
<tr>
<td>PL 315182 A</td>
<td>14-10-96</td>
<td></td>
</tr>
<tr>
<td>SK 83996 A</td>
<td>06-11-96</td>
<td></td>
</tr>
<tr>
<td>US 5612337 A</td>
<td>18-03-97</td>
<td></td>
</tr>
<tr>
<td>ZA 9418317 A</td>
<td>10-10-95</td>
<td></td>
</tr>
<tr>
<td>FI 951762 A</td>
<td>13-10-95</td>
<td></td>
</tr>
<tr>
<td>HR 950222 A</td>
<td>31-08-97</td>
<td></td>
</tr>
</tbody>
</table>

Form: PCT/ISA/210 (patent family annex) (July 1992)